One hundred and twenty one patients considered on clinical grounds to have non-asthmatic chronic airflow obstruction completed a double blind, crossover trial comparing oral prednisolone 40 mg per day with inhaled beclomethasone dipropionate 500 pg thrice daily, each given for 14 days, with a 14 day washout period between treatments. The time course of response was analysed for the 57 occasions where there was a significant increase in mean daily peak expiratory flow (PEF) over the treatment period. Mean daily PEF was still rising at day 14 on 12 occasions. After withdrawal of treatment mean daily PEF remained above pretreatment levels for more than two weeks in half the responses analysed. The peak response occurred earlier with inhaled beclomethasone (median 9 5 (range 3-14) days) than with oral prednisolone (median 12 (range 1-14) days), though both treatments produced a response that was sustained for a similar period. The results suggest that a trial of treatment with corticosteroids in this group of patients should last more than 14 days, and that in a study with a crossover design the washout period should be longer than two weeks.
It is common practice to give patients with non-asthmatic chronic airflow obstruction a trial of corticosteroids to identify patients in whom clinical improvement occurs. '2 In such trials the drug is usually given for two to four weeks, but the rationale for this duration of treatment is not clear. 3 In a group of predominantly asthmatic patients Webb et al showed that those responding to prednisolone did so by the eleventh day of treatment. 4 No comparable work has been carried out in patients with non-asthmatic airflow obstruction.
In a randomised, double blind crossover trial comparing placebo, inhaled beclomethasone, and oral prednisolone we showed that a response to placebo treatment was more likely to occur when this was preceded by an active treatment period, despite a two week washout period between treatments.5 This suggests a carry over effect of active treatment of at least three to four weeks as response to steroid treatment was not measured until four weeks after the previous treatment had been stopped.
We have analysed the time course of the response to oral and inhaled corticosteroids by assessing the time taken to reach a plateau in PEF with treatment in our crossover study' and the time taken for PEF to return to pretreatment levels after cessation of treatment.
Methods

SUBJECTS
Outpatients with chronic airflow obstruction of at least five years' duration were recruited to the trial. Patients were excluded if they had a clinical diagnosis of asthma. Details are given in the previous article. No patient had received oral or inhaled corticosteroids in the preceding six months. All patients gave informed consent.
DESIGN
The trial was a randomised, double blind, double dummy crossover comparison of inhaled beclomethasone dipropionate 500 pg thrice daily, oral prednisolone 40 mg/day, and placebo. Each treatment phase lasted two weeks and was followed by a two week washout period before the next treatment was given.
The first treatment period was preceded by a four week baseline period. Patients attended the laboratory on days 1 and 14 of the baseline period, and on the last day of each treatment period. Fourteen further patients who completed the same protocol without the placebo period are included in this analysis, as response to treatment has been defined without reference to the placebo period in view of the treatment 
